Recent Press Releases

Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisition of Z

Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisition of ZymoGenetics The Company Presented New Clinical Data from its Diabetes

Q3/2010: Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million

Q3/2010: Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million Total revenues increase 25% to record EUR 2.4 billion Operating result surges 64% to EUR 363 million, organic growth up

Amgen's Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year

Amgen's Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior YearThird Quarter 2010 Adjusted Earnings Per Share Decreased 9 Percent to $1.36Third Quarter 2010 GAAP Earnings Per Share

Microscan Introduces Complete Solution for Packaging Traceability

Product News NetworkOctober 20, 2010RENTON, WA - Microscan, a global technology leader for track and trace solutions, introduces the newest solution for inspecting and verifying package label

Nonprescription drugs cost structures fluctuate with increased cost of goods, according to Kline

A number of costs associated with nonprescription drug manufacturing and marketing have increased over the past two and a half years. Certain material costs for plastic bottles and blister packs have

CIS publishes Corrective Action/Preventative Action (CAPA) System White Paper

Compliance Implementation Services (CIS), a pharmaceutical compliance consulting firm, announced the publication of its white paper on compliance-focused approaches to establishing an efficient,

Big Pharma and Biotech Leaders to Converge in Shanghai, China at Asia Pharma R&D Leaders 2011 Summit to Discuss Novel R&D Approa

Pharma R&D 2011 and Beyond: Thinking Big, Acting SmallSHANGHAI, Oct. 26 /PRNewswire-Asia/ -- With closure and even divestiture of discovery sites in US and Europe in 2010, Big Pharma is under

Shire Receives INTUNIV(TM) Paragraph IV Notice Letter

Watson is the Fourth Paragraph IV Filer Against INTUNIVDUBLIN, October 26, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,

Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisitio

The Company Presented New Clinical Data from its Diabetes and Cardiovascular Franchises at Important Medical MeetingsAcquisition of ZymoGenetics Added to Strong Hepatitis C Portfolio and Demonstrated

Biogen Idec Reports Third Quarter 2010 Results

Double Digit EPS Growth Substantial Progress on TYSABRI® Risk Stratification WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery,

PharmaVentures Acts as Advisor and Broker to Dr Reddy's to Identify and Secure Product Marketing Opportunities for the Russian/C

OXFORD, England, October 26, 2010 /PRNewswire/ -- PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its

Immune Design Grants Adjuvant License to MedImmune

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today

Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year

Third Quarter 2010 Adjusted Earnings Per Share Decreased 9 Percent to $1.36THOUSAND OAKS, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported revenue unchanged for the third

Vertex Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibr

-Hepatitis C: New Drug Application submission for telaprevir on track for fourth quarter 2010- -Cystic Fibrosis: Phase 3 registration program ongoing for VX-770- -Pipeline: Ongoing proof-of-concept

Momenta Pharmaceuticals Awarded Second U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or

Momenta Pharmaceuticals Awarded Second U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or Chain Mapping CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) --

GlaxoSmithKline Inc. Drops the Price of CERVARIX

A Patient-Focused Response to Help Ensure All Canadian Women Have Greater Access to Protection Against Cervical Cancer MISSISSAUGA, ON, Oct. 25 /CNW/ - Today, GlaxoSmithKline Inc. (Canada), announced

Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test

Another Roche FDA approval in the COBAS® TaqMan® viral load portfolioPLEASANTON, Calif., Oct. 25 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug

Bionovo Comments on Recent Hormone Therapy (HT) Risk Disclosures

Bionovo Seeks to Develop HT Alternatives for Hot Flashes and Other Symptoms of MenopauseEMERYVILLE, Calif., Oct. 25 /PRNewswire/ -- Bionovo Inc. (Nasdaq: BNVI), a pharmaceutical company focused on

Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting

Intranasal Norovirus VLP Vaccine Demonstrates Clinical Efficacy When Compared to Placebo in Phase I/II TrialBOZEMAN, Mont., Oct. 25 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private,